Information Provided By:
Fly News Breaks for December 16, 2019
CRSP
Dec 16, 2019 | 13:34 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $104 price target on Crispr Therapeutics (CRSP) after the company completed the consolidation of the Casebia joint venture. The analyst added that Crispr and partner Vertex (VRTX) recently reported first-ever CTX001 data showing potentially curative effect in one beta thalassemia and one sickle cell disease patient, saying he anticipates updated data next year and could see accelerated approval based on only a few patients.
News For CRSP From the Last 2 Days
CRSP
Jun 14, 2021 | 16:07 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly. 1... To see the rest of the story go to thefly.com. See Story Here
CRSP
Jun 14, 2021 | 12:02 EDT
1. STOCK NEWS:Novavax (NVAX)... To see the rest of the story go to thefly.com. See Story Here
CRSP
Jun 14, 2021 | 09:53 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Strong Buy from Outperform at Raymond James with analyst Brian Vaccaro saying the recently announced menu price increases of 4% in recent weeks with more coming in the fall create "significant upside" to second half of 2021 consensus comp expectations. 2. Crispr Therapeutics (CRSP) upgraded to Neutral from Sell at Citi with analyst Yigal Nochomovitz saying it is becoming increasingly clear that CTX001 is demonstrating consistent durable increases in fetal hemoglobin that are yielding prolonged therapeutic benefit on transfusion-independence in beta-thalassemia and freedom from vaso-occlusive crisis in sickle-cell. 3. Wendy's (WEN) upgraded to Buy from Neutral at Northcoast with analyst Jim Sanderson saying channel checks are "just as compelling as ever" and indicate that Wendy's current performance is exceeding expectations. 4. Welltower (WELL) upgraded to Outperform from In Line at Evercore ISI with analyst Steve Sakwa citing improving SH operations, a better acquisition outlook and the potential for long-term margin expansion with the recent hiring of John Burkart. 5. Cheniere Energy Partners (CQP) upgraded to Buy from Neutral at Goldman Sachs with analyst Michael Lapides citing recent underperformance, its defensive and largely contracted asset base that offers visibility into stable cash flows and upside to consensus from tailwinds to Cheniere Energy Partners' commodity margins from global natural gas prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRSP
Jun 14, 2021 | 05:57 EDT
Citi analyst Yigal Nochomovitz upgraded Crispr Therapeutics to Neutral from Sell with a price target of $132, up from $55. It is becoming increasingly clear that CTX001 is demonstrating consistent durable increases in fetal hemoglobin that are yielding prolonged therapeutic benefit on transfusion-independence in beta-thalassemia and freedom from vaso-occlusive crisis in sickle-cell, Nochomovitz tells investors in a research note. As such, the analyst upwardly revise his valuation assumptions to reflect "lower risk to future revenues."